Nurse Practitioner, Family · Silver Spring, MD
NPI
1407207715
Since 2016
Specialty
Nurse Practitioner, Family
Code 363LF0000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1400 Forest Glen Rd Ste 435
Silver Spring, MD, 20910
Phone (301) 593-9035
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$2.1M
502 prescriptions
Company payments, 2025
$32.91
From 1 companies
Medicare prescription drug claims, 2024
In 2024, the drug Sejal N Vaidya prescribed most often to Medicare patients was Ruxience (Rituximab-Pvvr), with 86 prescriptions and refills. In total Sejal N Vaidya wrote 502 Medicare prescriptions that cost $2.1M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-06-28.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Ruxience Rituximab-Pvvr | 86 | 89 | 33 | $469K |
| Trazimera Trastuzumab-Qyyp | 69 | 69 | 24 | $301K |
| Zirabev Bevacizumab-Bvzr | 49 | 49 | 21 | $204K |
| Lupron Depot Leuprolide Acetate | 44 | 125 | 31 | $228K |
| Fulphila Pegfilgrastim-Jmdb | 34 | 34 | 16 | $75K |
| Procrit Epoetin Alfa | 31 | 31 | 23 | $53K |
| Eligard Leuprolide Acetate | 27 | 71 | 18 | $29K |
| Alymsys Bevacizumab-Maly | 23 | 23 | Under 11 | $163K |
| Nivestym Filgrastim-Aafi | 22 | 22 | Under 11 | $26K |
| Xgeva Denosumab | 22 | 23 | 14 | $67K |
| Zarxio Filgrastim-Sndz | 20 | 20 | Under 11 | $33K |
| Truxima Rituximab-Abbs | 17 | 17 | Under 11 | $113K |
Brand drugs: 488 claims; generic drugs: 14 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sejal N Vaidya $32.91 ($32.91 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $32.91.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $32.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.